Latest news

2024-01 – Q4 2023 Reporting
  • After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down.
  • Recruitment of patients in Australia remains very slow.
  • Private Placement of 1,3 mil B-shares was completed and the proceeds of app. NOK 17 received. It was furthermore decided to do a Subsequent Offering of B-shares in early 2024.

Read more here

2023-10 – Q3 2023 Reporting
  • Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study.
  • The broaden of inclusion criteria for recruitment of patients to the
    SER150 CL-009 study is about to be approved by both health
    authorities and the individual clinical centres.
  • The company raised app. NOK 17 M in a Private Placement.

Read more here

2023-09 – Q2 2023 Reporting
  • Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study.
  • To facilitate enrolment, the entrance criteria will be revised for the SER150 CL-009 study based on feedback from investigators and serial blood collections will be removed from the protocol. 
  • The company has initiated a share issue through a private placement to raise funds to finalize the SER150 Cl-009 clinical study.

Read more here

2023-06 – Investor Meeting in Copenhagen

Address:
Stokholmsgade 41
2100 Copenhagen E

June 21, 2023, at 15:00

Please reserve the date

2023-05 – 2022 Annual Report

Serodus ASA – Publishes 2022 Annual Report

Download it here

2023-04 – Q1 2023 Reporting
  • Serodus has visited all clinical centers in Australia and New Zealand
  • SER150/placebo dosing period has been prolonged from 3 to 6 months.

Read more here

2023-02 – Q4 2022 Reporting
  • New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months.
  • All clinical centers in Australia and New Zealand ready to initiate screening of patients in January for participation in study SER150 CL-009

Read more here